The Histamine H1-Receptor Antagonist Binding Site. A Stereoselective Pharmacophoric Model Based upon (Semi-)Rigid H1-Antagonists and Including a Known Interaction Site on the Receptor

Journal of Medicinal Chemistry
1995.0

Abstract

A new pharmacophoric model for the H1-antagonist binding site is derived which reveals that a simple atom to atom matching of compounds is not sufficient; in this model, interacting residues from the receptor need to be included. To obtain this model, the bioactive conformations of several (semi-)rigid classical histamine H1-receptor antagonists have been investigated (cyproheptadine, phenindamine, triprolidine, epinastine, mequitazine, IBF28145, and mianserine). In general, these antihistamines contain two aromatic rings and a basic nitrogen atom. A previously derived pharmacophoric model with the nitrogen position fixed relative to the two aromatic rings is now found not to be suitable for describing the H1-antagonist binding site. A procedure is described which allows for significant freedom in the position of the basic nitrogen of the histamine H1-antagonist. The area accessible to the basic nitrogen is confined to the region accessible to its counterion on the histamine H1-receptor, i.e., the carboxylate group of Asp116. The basic nitrogen is assumed to form an ionic hydrogen bond with this aspartic acid which C alpha- and C beta-carbons are fixed with respect to the protein backbone. Via this hydrogen bond, the direction of the acidic proton of the antagonist is taken into account. Within these computational procedures, an aspartic acid is coupled to the basic nitrogen of each H1-antagonist considered; the carboxylate group is connected to the positively charged nitrogen via geometric H-bonding restraints obtained from a thorough database search (CSD). Also to the basic nitrogen of the pharmacophore is coupled an aspartic acid (to yield our new template). In order to derive a model for the H1-antagonist binding site, the aromatic ring systems of the antagonists and template are matched according to a previously described procedure. Subsequently, the C alpha- and C beta-carbons of the aspartic acid coupled to the H1-antagonists are matched with those of the template in a procedure which allows the antagonist and the carboxylate group to adapt their conformation (and also their relative position) in order to optimize the overlap with the template. A six-point pharmacophoric model is derived which has stereoselective features and is furthermore able to distinguish between the so-called "cis"- and "trans"-rings mentioned in many (Q)SAR studies on H1-antagonists. Due to its stereoselectivity, the model is able to designate the absolute bioactive configuration of antihistamines such as phenindamine (S), epinastine (S), and IBF28145 (R). A further merit of this study is that a model is obtained which includes an amino acid from the receptor.(ABSTRACT TRUNCATED AT 400 WORDS)

Knowledge Graph

Similar Paper

The Histamine H1-Receptor Antagonist Binding Site. A Stereoselective Pharmacophoric Model Based upon (Semi-)Rigid H1-Antagonists and Including a Known Interaction Site on the Receptor
Journal of Medicinal Chemistry 1995.0
Design, synthesis, and docking studies of novel benzopyrone derivatives as H1-antihistaminic agents
Bioorganic & Medicinal Chemistry 2008.0
Characterization of the 5-HT<sub>7</sub>Receptor. Determination of the Pharmacophore for 5-HT<sub>7</sub>Receptor Agonism and CoMFA-Based Modeling of the Agonist Binding Site
Journal of Medicinal Chemistry 2003.0
Synthesis, Molecular Modeling Studies, and Pharmacological Activity of Selective A<sub>1</sub>Receptor Antagonists
Journal of Medicinal Chemistry 2002.0
Graphics computer-aided receptor mapping as a predictive tool for drug design: development of potent, selective, and stereospecific ligands for the 5-HT1A receptor
Journal of Medicinal Chemistry 1988.0
Histaprodifens:  Synthesis, Pharmacological in Vitro Evaluation, and Molecular Modeling of a New Class of Highly Active and Selective Histamine H<sub>1</sub>-Receptor Agonists
Journal of Medicinal Chemistry 2000.0
Synthesis and Pharmacological Identification of Neutral Histamine H<sub>1</sub>-Receptor Antagonists
Journal of Medicinal Chemistry 2003.0
Optimization of the Pharmacophore Model for 5-HT<sub>7</sub>R Antagonism. Design and Synthesis of New Naphtholactam and Naphthosultam Derivatives
Journal of Medicinal Chemistry 2003.0
Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics
Bioorganic &amp; Medicinal Chemistry Letters 2009.0
Development of a Receptor-Interaction Model for Serotonin 5-HT2 Receptor Antagonists. Predicting Selectivity with Respect to Dopamine D2 Receptors
Journal of Medicinal Chemistry 1994.0